NetraMark Delivers Transformational Quarter Of Execution
Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award Secured TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: A
(Financial Post, 2025-12-18T13:35:12Z)